Ajanta Pharma is a specialty pharmaceutical formulation company with focuses on only few socalled specialty therapies – ophthalmology, dermatology and cardiology. In the past five years, it has posted healthy performance with its consolidated revenue growing at 26 per cent CAGR, and net profit at 51 per cent CAGR.
Why: With focus on niche therapies in domestic formulations, it enjoys good track record of strong balance sheet with high return ratios.
What: Currency devaluations and forex scarcity in select geographies continue to pose challenges.
